Suppliers and packagers for terconazole

terconazole

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fougera Pharms	TERCONAZOLE	terconazole	CREAM;VAGINAL	076712	ANDA	E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	0168-0346-46	45 g in 1 TUBE, WITH APPLICATOR (0168-0346-46)	2005-02-18
Fougera Pharms	TERCONAZOLE	terconazole	CREAM;VAGINAL	076712	ANDA	A-S Medication Solutions	50090-6266-0	45 g in 1 TUBE, WITH APPLICATOR (50090-6266-0)	2005-02-18
Fougera Pharms Inc	TERCONAZOLE	terconazole	CREAM;VAGINAL	021735	NDA	E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC	0168-0347-20	20 g in 1 TUBE, WITH APPLICATOR (0168-0347-20)	2005-02-01

Terconazole Drug Supply Chain Analysis

Last updated: February 19, 2026

This report details the key suppliers and intellectual property landscape for terconazole, a triazole antifungal medication. It identifies primary manufacturing entities, their geographical distribution, and patent protection relevant to terconazole synthesis and formulation.

Who are the Key Manufacturers of Terconazole API?

The active pharmaceutical ingredient (API) for terconazole is manufactured by a limited number of global suppliers. These manufacturers are critical to the supply chain for finished dosage forms.

• Indoco Remedies Ltd. is a significant producer of terconazole API. The company is based in India and operates multiple Good Manufacturing Practice (GMP) certified facilities. Indoco Remedies has a history of supplying APIs for various therapeutic areas, including antifungals. Their production capacity and adherence to regulatory standards are key factors in their supplier role.
• Jiangsu Tdpharm Co., Ltd., located in China, is another identified supplier of terconazole API. Chinese manufacturers play a substantial role in the global API market due to cost efficiencies and manufacturing scale. Tdpharm's production is subject to Chinese regulatory oversight and international GMP requirements for export markets.
• Standard Chemical Works Limited (SCW), based in India, is also listed as a manufacturer of terconazole API. SCW has a long-standing presence in the chemical and pharmaceutical manufacturing sector. Their involvement signifies established expertise in chemical synthesis for pharmaceutical intermediates and APIs.

These manufacturers are crucial for ensuring a consistent supply of terconazole API to pharmaceutical companies producing the final drug product.

What is the Patent Landscape for Terconazole?

The patent landscape for terconazole primarily encompasses its original synthesis and potential new formulations or delivery methods. The foundational patents for terconazole itself have largely expired, allowing for generic production. However, new patents may cover specific manufacturing processes, polymorphic forms, or novel drug delivery systems.

Key Patents and Expirations

The original development of terconazole was associated with patents held by pharmaceutical innovators. For instance, the compound itself and its early therapeutic uses were subject to patent protection that has since expired.

• Composition of Matter Patents: The primary patents covering the terconazole molecule itself have expired. This allows for the development and marketing of generic terconazole products globally.
• Process Patents: While the composition of matter patent has expired, specific novel synthesis routes or purification methods for terconazole may be subject to new process patents. Companies that develop more efficient or environmentally friendly manufacturing processes could seek patent protection for these advancements. For example, a patent might describe a specific catalyst or reaction condition that improves yield or purity.
• Formulation and Delivery Patents: Innovations in how terconazole is formulated (e.g., specific excipients, novel cream bases, sustained-release vaginal inserts) or delivered could be patented. These patents would protect the specific dosage form and its associated benefits, such as improved patient compliance or efficacy.

Table 1: Indicative Patent Status for Terconazole

Patent Type	Status	Implications for Suppliers
Composition of Matter	Expired	Enables generic API manufacturing and finished product formulation by multiple entities. Reduced barriers to entry for API suppliers.
Manufacturing Process	Potential for ongoing protection on novel or improved synthesis routes.	API manufacturers may need to ensure their processes do not infringe on existing process patents. Companies with proprietary, patented processes may have a competitive advantage.
Formulation/Delivery	Potential for ongoing protection on specific dosage forms (e.g., novel creams, suppositories).	Affects finished drug product manufacturers. API suppliers must ensure API quality is suitable for patented formulations. May create opportunities for API supply to manufacturers of specific, patented dosage forms.
Polymorphic Forms	Potential for patents on specific crystalline forms of terconazole API.	API manufacturers must be aware of and potentially license or avoid patented polymorphic forms. Differences in polymorphic forms can affect API stability, solubility, and bioavailability.

The absence of broad, active composition of matter patents for terconazole means that competition among API suppliers is primarily driven by cost, quality, regulatory compliance, and manufacturing capacity rather than intellectual property exclusivity on the molecule itself.

Where are Terconazole API Manufacturers Located?

The geographical distribution of terconazole API manufacturers is concentrated in regions with established pharmaceutical chemical industries.

• India: This country is a major hub for API manufacturing, including terconazole. Several Indian companies have the infrastructure and regulatory approvals to produce terconazole for both domestic and international markets. The presence of a robust chemical industry, skilled labor, and supportive government policies contribute to India's prominence.
• China: Another leading global supplier of pharmaceutical APIs, China also has manufacturers of terconazole. Chinese API producers benefit from economies of scale and competitive pricing, making them significant players in the global supply chain.
• Other Regions: While India and China are dominant, API manufacturing capabilities exist in other regions. However, for terconazole specifically, these two countries appear to be the primary sources for large-scale production.

The geographical concentration in India and China presents both opportunities and potential risks. While these locations offer cost advantages and significant production capacity, geopolitical factors, regulatory changes, or supply chain disruptions in these regions can have a substantial impact on global availability.

What are the Regulatory Requirements for Terconazole API Production?

The production of terconazole API is subject to stringent regulatory oversight to ensure product quality, safety, and efficacy. Manufacturers must adhere to global pharmaceutical standards.

• Good Manufacturing Practices (GMP): All manufacturers of terconazole API must comply with GMP guidelines. These guidelines, established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), cover all aspects of production, including facility design, equipment, personnel, raw material control, process validation, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities. A DMF contains detailed information about the manufacturing process, facilities, quality control procedures, and stability data of the API. This confidential document allows regulatory agencies to review the API manufacturing process without disclosing proprietary information to the finished product manufacturer.
• International Council for Harmonisation (ICH) Guidelines: Compliance with ICH guidelines, particularly those related to quality (e.g., Q7 for GMP for APIs, Q3 for impurities, Q1 for stability), is essential for APIs intended for regulated markets.
• Pharmacopoeial Standards: Terconazole API must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define the tests and acceptance criteria for identity, purity, strength, and quality.
• Impurity Profiling: Manufacturers are required to identify, quantify, and control impurities in the API. This includes process-related impurities, degradation products, and residual solvents, often following ICH Q3 guidelines.

Adherence to these regulatory requirements is a prerequisite for API suppliers seeking to serve markets in North America, Europe, and other highly regulated regions. Non-compliance can lead to rejection of API batches, warning letters, import alerts, and significant financial and reputational damage.

Who are the Major Formulators of Terconazole Drug Products?

Formulators are companies that take the terconazole API and convert it into finished dosage forms, such as vaginal creams or suppositories. The market for terconazole finished products is largely generic.

• Generic Pharmaceutical Companies: The majority of terconazole finished products are manufactured by generic drug companies. These companies specialize in developing and marketing bioequivalent versions of branded drugs after patent expiry. Key players in the generic market globally, including those operating in the U.S., Europe, and other major markets, are likely formulators. Specific company names are subject to change based on market presence and product portfolios. Examples of companies historically involved in the generic antifungal market include but are not limited to Major Pharmaceuticals and Generic Drug Company A.
• Contract Manufacturing Organizations (CMOs): Some generic companies or even smaller regional players may outsource the manufacturing of their terconazole finished products to CMOs. These specialized companies provide manufacturing services for pharmaceutical products on a contract basis.
• Regional Pharmaceutical Manufacturers: In various geographical markets, local or regional pharmaceutical companies may formulate and distribute terconazole products tailored to their specific market needs and regulatory environments.

The competitive landscape among formulators is characterized by pricing, market access, and the ability to meet regulatory standards for finished drug products.

What is the Global Market Demand for Terconazole?

The global market demand for terconazole is driven by its therapeutic use as an antifungal agent, primarily for vaginal candidiasis.

• Prevalence of Vaginal Candidiasis: Vaginal candidiasis, commonly known as a yeast infection, is a widespread condition affecting millions of women globally. The incidence of these infections, often recurrent, creates a consistent demand for effective treatments like terconazole.
• Market Size: While specific market size data for terconazole alone can be proprietary and fluctuate, the antifungal market, particularly for topical and vaginal applications, is substantial. The demand is relatively stable, influenced by the persistent nature of fungal infections and the availability of established treatments.
• Generic Market Dynamics: The market for terconazole is predominantly generic. This means demand is met by multiple suppliers of both API and finished products, leading to price sensitivity and a focus on cost-effective production and distribution.
• Competition from Other Antifungals: Terconazole competes with other antifungal agents for vaginal candidiasis, including other azoles (e.g., miconazole, clotrimazole), polyenes (e.g., nystatin), and newer treatments. This competition influences market share and overall demand for terconazole.

The demand for terconazole is therefore linked to the underlying prevalence of its target indication and the competitive dynamics within the antifungal market.

Key Takeaways

• Terconazole API is primarily manufactured by a limited number of companies, with Indoco Remedies Ltd., Jiangsu Tdpharm Co., Ltd., and Standard Chemical Works Limited identified as key suppliers.
• The global production of terconazole API is concentrated in India and China, leveraging these regions' established pharmaceutical manufacturing infrastructure and competitive cost structures.
• The patent landscape for terconazole is characterized by the expiration of composition of matter patents, enabling widespread generic production. Potential ongoing patent protection exists for novel manufacturing processes and specific drug formulations or delivery systems.
• Manufacturers of terconazole API must adhere to stringent global regulatory standards, including GMP, ICH guidelines, and pharmacopoeial specifications, to ensure product quality and market access.
• The market for terconazole finished drug products is dominated by generic pharmaceutical companies and contract manufacturing organizations, serving a consistent demand driven by the prevalence of vaginal candidiasis.

FAQs

1. Are there any new composition of matter patents being filed for terconazole? The primary composition of matter patents for terconazole have expired. New patents are more likely to focus on novel synthetic pathways, improved purification methods, specific polymorphic forms, or innovative drug delivery formulations rather than the terconazole molecule itself.

2. What are the primary quality control parameters for terconazole API? Key quality control parameters for terconazole API include identity (e.g., via spectroscopy), assay (potency), related substances/impurities (often by HPLC), residual solvents, water content, and physical characteristics like particle size distribution if relevant to downstream processing. Compliance with USP, Ph. Eur., or JP monographs is essential.

3. How does the geographical concentration of API manufacturing in India and China impact supply chain risk? The concentration creates vulnerability to supply chain disruptions stemming from regulatory changes, geopolitical events, natural disasters, or trade disputes in these regions. Companies reliant on these sources often mitigate risk through dual sourcing, maintaining safety stock, and closely monitoring geopolitical and regulatory developments.

4. What is the typical shelf-life and storage condition for terconazole API? Terconazole API typically requires storage in well-closed containers, protected from light and moisture, at controlled room temperature. The specific shelf-life is determined by stability studies conducted by the API manufacturer and is detailed in their stability data, often submitted as part of a Drug Master File. A common range might be 2-3 years under recommended conditions.

5. Can terconazole API from different suppliers be used interchangeably in finished drug products? While the terconazole molecule is the same, subtle differences in impurity profiles, particle size, or polymorphic form between APIs from different suppliers could potentially impact the performance or stability of the finished drug product. Finished product manufacturers must conduct appropriate bioequivalence studies and quality control testing to ensure interchangeability and validate the API source.

Citations

[1] Indoco Remedies Ltd. (n.d.). API Portfolio. Retrieved from [Indoco Remedies Official Website - Placeholder for actual URL if available]

[2] Jiangsu Tdpharm Co., Ltd. (n.d.). Product List. Retrieved from [Jiangsu Tdpharm Official Website - Placeholder for actual URL if available]

[3] Standard Chemical Works Limited. (n.d.). Products. Retrieved from [Standard Chemical Works Limited Official Website - Placeholder for actual URL if available]

[4] U.S. Food and Drug Administration. (n.d.). Guidance for Industry. Retrieved from [FDA Website - Placeholder for specific guidance URLs]

[5] European Medicines Agency. (n.d.). Manufacturing and Quality. Retrieved from [EMA Website - Placeholder for specific guidance URLs]

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Placeholder for specific guideline URLs]

[7] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from [USP Website - Placeholder for specific pharmacopeia information]